Evaluation of Transarterial Chemoembolization Protocol with Drug-Eluting Beads in Combination with Lipiodol for Hepatocellular Carcinoma: A Single-Center Controlled Study

Table 1

Baseline characteristics.

Characteristics	D-TACE group (N = 293)	D-TACE + lipiodolgroup (N = 34)	value
	(No, %; mean ± SD)	(No, %; mean ± SD)
Gender
Male	243 (82.9%)	30 (88.2%)	0.431
Female	50 (17.1%)	4 (11.8%)
Age (years)	56.9 ± 11.1	55.0 ± 11.8	0.353
BCLC class
A	81 (27.6%)	12 (35.3%)	0.572
B	75 (25.6%)	9 (26.5%)
C	137 (46.8%)	13 (38.2%)
Hepatitis
Hepatitis B	221 (75.4%)	27 (79.4%)	0.607
Other	72 (24.6%)	7 (20.6%)
Child-pugh score
A	239 (81.6%)	30 (88.2%)	0.335
B	54 (18.4%)	4 (11.8%)
B7	49	2
B8	4	1
B9	1	1
TB (µmol/L)	21.0 ± 14.1	17.9 ± 7.1	0.198
Albumin (g/L)	35.4 ± 6.1	36.3 ± 5.6	0.422
PT (s)	14.1 ± 1.5	14.2 ± 1.6	0.584
AST (µmol/L)	78.5 ± 100.3	88.0 ± 99.8	0.602
ALT (µmol/L)	60.8 ± 99.7	63.3 ± 47.5	0.889
PLR	150.6 ± 98.1	133.9 ± 72.7	0.338
NLR	4.3 ± 6.6	3.3 ± 2.0	0.347
Tumor size (cm)	8.0 ± 4.3	9.5 ± 4.9	0.08
Tumor number
≤3	291 (99.3%)	33 (97.1%)	0.191
>3	2 (0.7%)	1 (2.9%)
α-Fetoprotein level
>400 ng/mL	122 (41.6%)	18 (52.9%)	0.207
≤400 ng/ml	171 (58.4%)	16 (47.1%)
Ascites
Absent	246 (84.0%)	30 (88.2%)	0.515
Present	47 (16.0%)	4 (11.8%)
TACE sessions	3.45 ± 2.2	3.91 ± 2.2	0.238

Note. D-TACE: drug-elutingbeads-transcatheter arterial chemoembolization; SD: standard deviation; BCLC: barcelona clinical liver cancer; TB: total bilirubin; PT: prothrombin time; AST: aspartate aminotransferase; ALT: alanine aminotransferase; PLR: platelet-to-lymphocyte ratio; NLR: neutrophil-to-lymphocyte ratio.